HU-308

A specific agonist for CB2, a peripheral cannabinoid receptor

L Hanus, A Breuer, S Tchilibon, S Shiloah, D Goldenberg, M Horowitz, R G Pertwee, R A Ross, R Mechoulam, E Fride

Research output: Contribution to journalArticle

425 Citations (Scopus)

Abstract

Two cannabinoid receptors have been identified: CB1, present in the central nervous system (CNS) and to a lesser extent in other tissues, and CB2, present outside the CNS, in peripheral organs. There is evidence for the presence of CB2-like receptors in peripheral nerve terminals. We report now that we have synthesized a CB2-specific agonist, code-named HU-308. This cannabinoid does not bind to CB1 (K-i > 10 mu M), but does so efficiently to CB2 (K-i = 22.7 +/- 3.9 nM); it inhibits forskolin-stimulated cyclic AMP production in CB2-transfected cells, but does so much less in CB1-transfected cells. HU-308 shows no activity in mite in a tetrad of behavioral tests, which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the CNS mediated by CB1. However, HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity. The hypotension, the inhibition of defecation, the anti-inflammatory and peripheral analgesic effects produced by HU-308, are blocked (or partially blocked) by the CB2 antagonist SR-144528, but not by the CB1 antagonist SR-141716A. These results demonstrate the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain.

Original languageEnglish
Pages (from-to)14228-14233
Number of pages6
JournalPNAS
Volume96
Issue number25
DOIs
Publication statusPublished - 7 Dec 1999

Keywords

  • endogenous cannabinoids
  • induced hypotension
  • brain constituent
  • anandamide
  • identification
  • pharmacology
  • motility
  • ligands
  • analogs
  • binds

Cite this

Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., ... Fride, E. (1999). HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. PNAS, 96(25), 14228-14233. https://doi.org/10.1073/pnas.96.25.14228

HU-308 : A specific agonist for CB2, a peripheral cannabinoid receptor. / Hanus, L ; Breuer, A ; Tchilibon, S ; Shiloah, S ; Goldenberg, D ; Horowitz, M ; Pertwee, R G ; Ross, R A ; Mechoulam, R ; Fride, E .

In: PNAS, Vol. 96, No. 25, 07.12.1999, p. 14228-14233.

Research output: Contribution to journalArticle

Hanus, L, Breuer, A, Tchilibon, S, Shiloah, S, Goldenberg, D, Horowitz, M, Pertwee, RG, Ross, RA, Mechoulam, R & Fride, E 1999, 'HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor', PNAS, vol. 96, no. 25, pp. 14228-14233. https://doi.org/10.1073/pnas.96.25.14228
Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M et al. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. PNAS. 1999 Dec 7;96(25):14228-14233. https://doi.org/10.1073/pnas.96.25.14228
Hanus, L ; Breuer, A ; Tchilibon, S ; Shiloah, S ; Goldenberg, D ; Horowitz, M ; Pertwee, R G ; Ross, R A ; Mechoulam, R ; Fride, E . / HU-308 : A specific agonist for CB2, a peripheral cannabinoid receptor. In: PNAS. 1999 ; Vol. 96, No. 25. pp. 14228-14233.
@article{55ada164fc8a4134923ad7a0a2d566d6,
title = "HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor",
abstract = "Two cannabinoid receptors have been identified: CB1, present in the central nervous system (CNS) and to a lesser extent in other tissues, and CB2, present outside the CNS, in peripheral organs. There is evidence for the presence of CB2-like receptors in peripheral nerve terminals. We report now that we have synthesized a CB2-specific agonist, code-named HU-308. This cannabinoid does not bind to CB1 (K-i > 10 mu M), but does so efficiently to CB2 (K-i = 22.7 +/- 3.9 nM); it inhibits forskolin-stimulated cyclic AMP production in CB2-transfected cells, but does so much less in CB1-transfected cells. HU-308 shows no activity in mite in a tetrad of behavioral tests, which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the CNS mediated by CB1. However, HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity. The hypotension, the inhibition of defecation, the anti-inflammatory and peripheral analgesic effects produced by HU-308, are blocked (or partially blocked) by the CB2 antagonist SR-144528, but not by the CB1 antagonist SR-141716A. These results demonstrate the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain.",
keywords = "endogenous cannabinoids, induced hypotension, brain constituent, anandamide, identification, pharmacology, motility, ligands, analogs, binds",
author = "L Hanus and A Breuer and S Tchilibon and S Shiloah and D Goldenberg and M Horowitz and Pertwee, {R G} and Ross, {R A} and R Mechoulam and E Fride",
year = "1999",
month = "12",
day = "7",
doi = "10.1073/pnas.96.25.14228",
language = "English",
volume = "96",
pages = "14228--14233",
journal = "PNAS",
issn = "0027-8424",
publisher = "NATL ACAD SCIENCES",
number = "25",

}

TY - JOUR

T1 - HU-308

T2 - A specific agonist for CB2, a peripheral cannabinoid receptor

AU - Hanus, L

AU - Breuer, A

AU - Tchilibon, S

AU - Shiloah, S

AU - Goldenberg, D

AU - Horowitz, M

AU - Pertwee, R G

AU - Ross, R A

AU - Mechoulam, R

AU - Fride, E

PY - 1999/12/7

Y1 - 1999/12/7

N2 - Two cannabinoid receptors have been identified: CB1, present in the central nervous system (CNS) and to a lesser extent in other tissues, and CB2, present outside the CNS, in peripheral organs. There is evidence for the presence of CB2-like receptors in peripheral nerve terminals. We report now that we have synthesized a CB2-specific agonist, code-named HU-308. This cannabinoid does not bind to CB1 (K-i > 10 mu M), but does so efficiently to CB2 (K-i = 22.7 +/- 3.9 nM); it inhibits forskolin-stimulated cyclic AMP production in CB2-transfected cells, but does so much less in CB1-transfected cells. HU-308 shows no activity in mite in a tetrad of behavioral tests, which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the CNS mediated by CB1. However, HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity. The hypotension, the inhibition of defecation, the anti-inflammatory and peripheral analgesic effects produced by HU-308, are blocked (or partially blocked) by the CB2 antagonist SR-144528, but not by the CB1 antagonist SR-141716A. These results demonstrate the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain.

AB - Two cannabinoid receptors have been identified: CB1, present in the central nervous system (CNS) and to a lesser extent in other tissues, and CB2, present outside the CNS, in peripheral organs. There is evidence for the presence of CB2-like receptors in peripheral nerve terminals. We report now that we have synthesized a CB2-specific agonist, code-named HU-308. This cannabinoid does not bind to CB1 (K-i > 10 mu M), but does so efficiently to CB2 (K-i = 22.7 +/- 3.9 nM); it inhibits forskolin-stimulated cyclic AMP production in CB2-transfected cells, but does so much less in CB1-transfected cells. HU-308 shows no activity in mite in a tetrad of behavioral tests, which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the CNS mediated by CB1. However, HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity. The hypotension, the inhibition of defecation, the anti-inflammatory and peripheral analgesic effects produced by HU-308, are blocked (or partially blocked) by the CB2 antagonist SR-144528, but not by the CB1 antagonist SR-141716A. These results demonstrate the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain.

KW - endogenous cannabinoids

KW - induced hypotension

KW - brain constituent

KW - anandamide

KW - identification

KW - pharmacology

KW - motility

KW - ligands

KW - analogs

KW - binds

U2 - 10.1073/pnas.96.25.14228

DO - 10.1073/pnas.96.25.14228

M3 - Article

VL - 96

SP - 14228

EP - 14233

JO - PNAS

JF - PNAS

SN - 0027-8424

IS - 25

ER -